National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus

• Published in: Sakharnyĭ diabet Vol. 26; no. 6; pp. 619 - 625
• Main Authors: Shestakova, M. V., Vagapova, G. R., Vikulova, O. K., Galstyan, G. R., Demidova, T. Yu, Dudinskaya, E. N., Kiseleva, T. P., Mkrtumyan, A. M., Petunina, N. A., Tkacheva, O. N., Fadeev, V. V., Khalimov, Y. S., Shestakova, E. A.
• Format: Journal Article
• Language: English
• Published: Endocrinology Research Centre 06-12-2023
• Subjects: dpp-4 inhibitors; gliptins; sitagliptin; type 2 diabetes mellitus
• ISSN: 2072-0351; 2072-0378
• DOI: 10.14341/DM13110

TThe annual increase in the prevalence of type 2 diabetes mellitus emphasizes the relevance of the search for new treatment options, along with necessity for regular review of proven therapeutic solutions. Today, dipeptidyl peptidase-4 inhibitors (DPP-4i, gliptins) are effective and safe hypoglycemic therapy, which is included in modern standards of treatment of type 2 diabetes. In 2022, the availability of this group of drugs for Russian patients has significantly increased. This circumstance became a prerequisite for holding a National Council of Experts with the participation of members of the Russian Association of Endocrinologists. The task of the Council was to determine the place of DPP-4i in the treatment of patients with type 2 diabetes in 2023. During the meeting of the Council, experts summarized the evidence base of DPP-4i taking into account the latest scientific data and determined the optimal clinical portraits of patients for the use of DPP-4i in accordance with updated national recommendations.